Vera Therapeutics, Inc.
33.78USD
-1.5000 (-4.25%)
Consensus EPS on the street’s adjusted basis, not the filed GAAP figure — which is why the actuals here can differ from the income statement.
| Period | Consensus EPS | 90 days ago | Revisions up (30d) | Revisions down (30d) |
|---|---|---|---|---|
| Current quarter | $-1.64▼ | $-1.64 | 2 | 5 |
| Next quarter | $-1.58▼ | $-1.43 | 4 | 3 |
| Current year | $-6.33▼ | $-6.29 | 4 | 3 |
| Next year | $-4.64▼ | $-3.8 | 2 | 5 |
Beat in 1 of the last 4
| Quarter | Estimate | Actual | Surprise |
|---|---|---|---|
| 2026-06-30 | $-1.59 | $-1.52 | +0.07 (+4.4%) |
| 2026-03-31 | $-1.37 | $-1.69 | -0.32 (-23.0%) |
| 2025-12-31 | $-1.27 | $-1.39 | -0.12 (-9.7%) |
| 2025-09-30 | $-1.13 | $-1.26 | -0.13 (-11.7%) |
76 ratings from 16 firms
Ratings are attributed to the research firm, not to individual analysts. See every ticker.
| Firm | Action | Rating | Price Target | Date |
|---|---|---|---|---|
| JP Morgan | Maintained | Overweight | $76 $83 | Sep 8, 2026 |
| Wedbush | Reiterated | Neutral | $34 | Aug 17, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $125 $90 | Aug 12, 2026 |
| Wedbush | Maintained | Neutral | $43 $34 | Aug 11, 2026 |
| TD Cowen | Maintained | Buy | $73 $78 | Jul 8, 2026 |
| Guggenheim | Maintained | Buy | $56 $76 | Jul 8, 2026 |
| Wedbush | Maintained | Neutral | $35 $43 | Jul 8, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $110 $125 | Jul 8, 2026 |
| B of A Securities | Maintained | Buy | $65 $70 | Jul 7, 2026 |
| Evercore ISI Group | Maintained | Outperform | $95 $91 | May 15, 2026 |
| Wolfe Research | Upgraded from Peer Perform | Outperform | $88 | Mar 11, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $90 $110 | Mar 2, 2026 |
| B of A Securities | Maintained | Buy | $48 $66 | Dec 19, 2025 |
| Goldman Sachs | Maintained | Buy | $55 $95 | Dec 19, 2025 |
| JP Morgan | Maintained | Overweight | $99 $96 | Dec 19, 2025 |
| Wedbush | Maintained | Neutral | $23 $33 | Dec 11, 2025 |
| Evercore ISI Group | Maintained | Outperform | $75 $97 | Dec 8, 2025 |
| TD Cowen | Maintained | Buy | $60 $73 | Dec 5, 2025 |
| HC Wainwright & Co. | Maintained | Buy | $85 $90 | Nov 10, 2025 |
| JP Morgan | Maintained | Overweight | $53 $52 | Nov 7, 2025 |
| B of A Securities | Initiated | Buy | $48 | Oct 16, 2025 |
| JP Morgan | Maintained | Overweight | $56 $53 | Aug 7, 2025 |
| Wolfe Research | Downgraded from Outperform | Peer Perform | — | Aug 4, 2025 |
| Scotiabank | Maintained | Sector Outperform | $55 $65 | Jun 2, 2025 |
| HC Wainwright & Co. | Maintained | Buy | $75 $85 | Jun 2, 2025 |
68 filings from 13 insiders · 7 buy / 8 sell over 6m
Officers and directors of VERA, from the last two years of filings. Grants, gifts and option exercises are shown but not colour-coded — they are compensation, not a view on the price.
| Insider | Action | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Fordyce MarshallDirector; Officer, PRESIDENT AND CEO | ExerciseStock Option (Right to Buy) | 18.5k | — | — | Sep 2, 2026 |
| Fordyce MarshallDirector; Officer, PRESIDENT AND CEO | Sell | 18.5k | $35.12 | $650k | Sep 2, 2026 |
| Fordyce MarshallDirector; Officer, PRESIDENT AND CEO | Exercise | 18.5k | $2.90 | $54k | Sep 2, 2026 |
| BOMAN NANCY LEE M.D., PH.D.Officer | Grant | 45.0k | — | — | Aug 3, 2026 |
| FORDYCE MARSHALLChief Executive Officer | Sell | 46.3k | $40.78 | $1.96M | Jul 7, 2026 |
| FORDYCE MARSHALLChief Executive Officer | Exercise | 46.3k | $2.90 | $134k | Jul 7, 2026 |
| FORDYCE MARSHALLChief Executive Officer | Sell | 18.5k | $37.93 | $702k | Jun 23, 2026 |
| FORDYCE MARSHALLChief Executive Officer | Exercise | 18.5k | $2.90 | $54k | Jun 23, 2026 |
| FORDYCE MARSHALLChief Executive Officer | Sell | 18.5k | $36.64 | $680k | May 12, 2026 |
| FORDYCE MARSHALLChief Executive Officer | Exercise | 18.5k | $2.90 | $54k | May 12, 2026 |
| FORDYCE MARSHALLChief Executive Officer | Sell | 23.0k | $43.66 | $1.01M | Apr 14, 2026 |
| WRIGHT-MITCHELL CATHERINE JANEOfficer | Grant | 42.4k | — | — | Mar 23, 2026 |
| YOUNG JOSEPH ROfficer | Exercise | 10.0k | $3.94 | $39k | Mar 13, 2026 |
| TURNER WILLIAM DONALDOfficer | Sell | 2.2k | $41.98 | $92k | Feb 23, 2026 |
| FORDYCE MARSHALLChief Executive Officer | Sell | 16.9k | $41.98 | $711k | Feb 23, 2026 |
| YOUNG JOSEPH ROfficer | Sell | 3.1k | $41.98 | $131k | Feb 23, 2026 |
| GRANT SEANChief Financial Officer | Sell | 4.9k | $41.98 | $208k | Feb 23, 2026 |
| BRENNER ROBERTOfficer | Sell | 2.2k | $41.98 | $90k | Feb 23, 2026 |
| JOHNSON DAVID LEEChief Operating Officer | Sell | 2.6k | $41.98 | $108k | Feb 23, 2026 |
| SKELTON LAURENCE MATTHEWOfficer | Sell | 1.6k | $41.98 | $66k | Feb 23, 2026 |
No analyst notes on VERA yet.
Analyst Ratings
14 analysts covering
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Consensus |
|---|---|---|---|---|---|---|
| Current | 1 | 12 | 1 | 0 | 0 | Buy2.00 |
| 1 mo ago | 1 | 12 | 1 | 0 | 0 | Buy2.00 |
| 2 mo ago | 1 | 12 | 1 | 0 | 0 | Buy2.00 |
| 3 mo ago | 1 | 12 | 1 | 0 | 0 | Buy2.00 |